Journal Club With Dr. Peter Attia | Metformin for Longevity & the Power of Belief Effects
Huberman Lab Podcast Recap
Published:
Duration: 3 hr 14 min
Guests: Dr. Peter Attia, Dr. Ali Crum
Summary
Dr. Peter Attia joins Andrew Huberman to discuss the potential longevity benefits of metformin, a common diabetes drug, and the intriguing relationship between belief and biological outcomes. The episode provides insights into how belief effects can influence drug efficacy and explores the...
What Happened
Dr. Peter Attia, a leading expert in health and lifespan, talks about the drug metformin, typically used for type 2 diabetes, and its potential as a geroprotective agent that may protect against aging. He discusses a 2014 study by Bannister that suggested type 2 diabetics on metformin had a survival advantage over non-diabetics, which piqued interest in its longevity benefits.
Attia explains that metformin's primary mechanism is inhibiting complex one of the mitochondria, which reduces hepatic glucose output. Despite its benefits in managing diabetes, metformin did not show a lifespan extension in the gold-standard Interventions Testing Program for animal studies. He also mentions his personal experience with metformin, which initially caused nausea due to improper dosage titration.
The episode looks at the Keys study, which used a large sample size from a Danish health registry to examine metformin's impact on mortality. The study revealed no significant mortality advantage for metformin users, contrasting with earlier findings. This highlights the difficulties in eliminating biases in large epidemiological studies.
The discussion shifts to the placebo effect and its dose-response relationship, particularly using nicotine as a case study. Attia and Huberman describe a study where participants' belief about nicotine dosage affected their brain activity, emphasizing the power of belief in drug efficacy.
Ali Crum's research is cited, showing that perceptions can alter biological responses, such as stress affecting performance and calorie perception impacting hunger hormone levels. The episode underscores the need for more reliable biomarkers for aging to assess interventions like metformin and fasting.
Huberman also provides a framework for critically assessing scientific papers, focusing on the importance of evaluating conclusions based on data. He explains how to read papers effectively by identifying key aspects like the question posed, approach taken, and findings.
The episode concludes with a discussion on the TAME trial, which aims to rigorously assess metformin's effects on aging in non-diabetics. This trial is expected to provide more definitive answers about metformin's potential geroprotective benefits.
Throughout the episode, the importance of energy balance over specific meal constituents for glucose homeostasis is reiterated, highlighting the complex interplay between lifestyle factors and health outcomes.
Key Insights
- Metformin, a drug used for over 50 years primarily for type 2 diabetes, may have potential geroprotective benefits, though its impact on longevity in humans remains controversial. Dr. Peter Attia cites the Bannister study, which suggested a survival advantage for diabetics on metformin, but notes mixed results in subsequent studies.
- Belief effects can significantly alter biological outcomes, as demonstrated by a study where participants' belief about nicotine dosage influenced brain activity in areas like the thalamus and ventromedial prefrontal cortex. This suggests that belief can sometimes bypass pharmacological effects.
- The TAME trial is a major clinical study aiming to assess metformin's geroprotective effects in non-diabetics. Expected to shed light on aging interventions, it underscores the need for rigorous testing to confirm any longevity benefits of metformin.
- Dr. Peter Attia and Andrew Huberman highlight the challenges of epidemiological studies in eliminating biases, such as medication mismatches in control groups. The Keys study, for instance, found no mortality advantage for metformin users, contrasting with earlier findings.